• Publications
  • Influence
GOLPH3 modulates mTOR signaling and rapamycin sensitivity in cancer
Genome-wide copy number analyses of human cancers identified a frequent 5p13 amplification in several solid tumour types, including lung (56%), ovarian (38%), breast (32%), prostate (37%) andExpand
Programmed death ligand-1 expression in non-small cell lung cancer
Multivariate analysis showed that PD-L1 expression was significantly associated with better outcome independent of histology and further studies are required to determine the value of this marker in prognosis and prediction of response to treatments targeting this pathway. Expand
Neoadjuvant PD‐1 Blockade in Resectable Lung Cancer
Nivolumab was associated with few side effects, did not delay surgery, and induced a major pathological response in 45% of resected tumors, and the tumor mutational burden was predictive of the pathological response to PD‐1 blockade. Expand
Clinical implications of genomic alterations in the tumour and circulation of pancreatic cancer patients.
These analyses reveal somatic mutations in chromatin-regulating genes MLL, M LL2, MLL3 and ARID1A in 20% of patients that are associated with improved survival and have implications for new avenues of therapeutic intervention. Expand
The Genomic Landscape of Response to EGFR Blockade in Colorectal Cancer
A systematic approach to evaluating response to targeted therapies in human cancer is provided, new mechanisms of responsiveness to anti-EGFR therapies are highlighted, and new avenues for intervention in managing colorectal cancer are delineated. Expand
Direct detection of early-stage cancers using circulating tumor DNA
In patients with resectable colorectal cancers, higher amounts of preoperative circulating tumor DNA were associated with disease recurrence and decreased overall survival, and a method developed by Phallen et al., called targeted error correction sequencing, demonstrates the feasibility of detecting circulating cell-free DNA from many early tumors, suggesting its potential use for cancer screening. Expand
Evolution of Neoantigen Landscape during Immune Checkpoint Blockade in Non-Small Cell Lung Cancer.
This work demonstrates for the first time that acquired resistance to immune checkpoint blockade can arise in association with the evolving landscape of mutations, some of which encode tumor neoantigens recognizable by T cells. Expand
Antibody validation.
This review highlights the common pitfalls when working with antibodies, common practices for validating antibodies, and levels of commercial antibody validation for seven vendors, and shares the algorithm for antibodies validation for immunohistochemistry and quantitative immunofluorescence. Expand
Genome-wide cell-free DNA fragmentation in patients with cancer
An approach to evaluate fragmentation patterns of cell-free DNA across the genome was developed, and found that profiles of healthy individuals reflected nucleosomal patterns of white blood cells, whereas patients with cancer had altered fragmentation profiles. Expand
Gefitinib or Placebo in Combination with Tamoxifen in Patients with Hormone Receptor–Positive Metastatic Breast Cancer: A Randomized Phase II Study
In stratum 1, the improved PFS with gefitinib plus tamoxifen met the protocol criteria to warrant further investigation of this strategy; in stratum 2, there was a numerical disadvantage for gef itinib; additional investigation after AI therapy is not warranted. Expand